

Sabina Antonela Antoniu

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8965472/sabina-antonela-antoniou-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

117
papers

721
citations

13
h-index

20
g-index

126
ext. papers

823
ext. citations

5.3
avg, IF

4.98
L-index

#	Paper	IF	Citations
117	Targeting RhoA/ROCK pathway in pulmonary arterial hypertension. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16, 355-63	6.4	46
116	Targeting PDGF pathway in pulmonary arterial hypertension. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16, 1055-63	6.4	30
115	Pirfenidone for the treatment of idiopathic pulmonary fibrosis. <i>Expert Opinion on Investigational Drugs</i> , 2006 , 15, 823-8	5.9	30
114	Inhaled colistin for lower respiratory tract infections. <i>Expert Opinion on Drug Delivery</i> , 2012 , 9, 333-42	8	29
113	Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. <i>N Engl J Med</i> 2010;363(18):1693-703. <i>Expert Opinion on Therapeutic Targets</i> , 2011 , 15, 351-3	6.4	29
112	Targeting the TNF-alpha pathway in sarcoidosis. <i>Expert Opinion on Therapeutic Targets</i> , 2010 , 14, 21-9	6.4	28
111	New therapeutic options in the management of COPD - focus on roflumilast. <i>International Journal of COPD</i> , 2011 , 6, 147-55	3	24
110	Measuring fatigue as a symptom in COPD: From descriptors and questionnaires to the importance of the problem. <i>Chronic Respiratory Disease</i> , 2015 , 12, 179-88	3	22
109	Anti-TNF-alpha therapies in chronic obstructive pulmonary diseases. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 1203-11	5.9	21
108	Impact of fatigue in patients with chronic obstructive pulmonary disease: results from an exploratory study. <i>Therapeutic Advances in Respiratory Disease</i> , 2016 , 10, 26-33	4.9	20
107	Predictors of Mortality in Patients with COPD and Chronic Respiratory Failure: The Quality-of-Life Evaluation and Survival Study (QuESS): A Three-Year Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016 , 13, 130-8	2	18
106	Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis. <i>Expert Review of Anti-Infective Therapy</i> , 2015 , 13, 897-905	5.5	14
105	Adherence to inhaled therapy in COPD: effects on survival and exacerbations. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010 , 10, 115-7	2.2	14
104	Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?. <i>Multidisciplinary Respiratory Medicine</i> , 2012 , 7, 41	3	13
103	Therapeutic approaches in hereditary angioedema. <i>Clinical Reviews in Allergy and Immunology</i> , 2011 , 41, 114-22	12.3	13
102	Effects of inhaled therapy on biomarkers of systemic inflammation in stable chronic obstructive pulmonary disease. <i>Biomarkers</i> , 2010 , 15, 97-103	2.6	13
101	Pitrakinra for asthma. <i>Expert Opinion on Biological Therapy</i> , 2010 , 10, 1609-15	5.4	13

100	Targeting 5-lipoxygenase-activating protein in asthma and chronic obstructive pulmonary disease. <i>Expert Opinion on Therapeutic Targets</i> , 2014 , 18, 1285-92	6.4	12
99	Inhaled ciprofloxacin for chronic airways infections caused by <i>Pseudomonas aeruginosa</i> . <i>Expert Review of Anti-Infective Therapy</i> , 2012 , 10, 1439-46	5.5	12
98	Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a Phase II randomized study. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 671-3	5.9	12
97	UPLIFT Study: the effects of long-term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Evaluation of: Tashkin DP, Celli B, Senn S et al.: a 4-year trial of tiotropium in chronic obstructive pulmonary disease. <i>N Engl J Med</i> (2008) 359(15):1543-1554. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 719-22	4	12
96	GM-CSF pathway correction in pulmonary alveolar proteinosis. <i>Expert Opinion on Biological Therapy</i> , 2010 , 10, 1357-65	5.4	11
95	Cytokine antagonists for the treatment of asthma: progress to date. <i>BioDrugs</i> , 2009 , 23, 241-51	7.9	11
94	MP-376 (Aeroquin) for chronic <i>Pseudomonas aeruginosa</i> infections. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 267-76	5.9	10
93	Health status during hospitalisations for chronic obstructive pulmonary disease exacerbations: the validity of the Clinical COPD Questionnaire. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014 , 14, 283-7	2.2	10
92	Mepolizumab for difficult-to-control asthma with persistent sputum eosinophilia. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 869-71	5.9	9
91	Targeting the angiotensin pathway in idiopathic pulmonary fibrosis. <i>Expert Opinion on Therapeutic Targets</i> , 2008 , 12, 1587-90	6.4	9
90	Discontinued drugs 2011: pulmonary, allergy, gastrointestinal and arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 1607-18	5.9	8
89	Inhaled gentamicin in non-cystic fibrosis bronchiectasis: effects of long-term therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1191-4	4	8
88	Golimumab for severe asthma. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 1421-3	5.9	8
87	Pharmacotherapy of cough-variant asthma. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 3021-8	4	8
86	Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting?. <i>Expert Opinion on Investigational Drugs</i> , 2006 , 15, 181-4	5.9	7
85	Sildenafil citrate for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 825-8	4	7
84	Monoclonal antibodies for asthma and chronic obstructive pulmonary disease. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 257-68	5.4	6
83	Raxibacumab for inhalational anthrax: an effective specific therapeutic approach?. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 909-11	5.9	6

82	Daclizumab a novel corticosteroid-sparing therapy for asthma?. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 369-71	5.9	6
81	Infliximab for the therapy of chronic sarcoidosis, Baughman RP, Drent M, Kavuru M et al.: Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. <i>Am. J. Respir. Crit. Care Med.</i> (2006) 174(7):795-802. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 753-6	5.9	6
80	Lebrikizumab for the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 1239-49	5.9	5
79	Hospitalizations for chronic obstructive pulmonary disease exacerbations and their impact on disease and subsequent morbidity and mortality. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013 , 13, 187-9	2.2	5
78	Combined long-acting bronchodilator single therapy for COPD. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 139-42	4	5
77	Tralokinumab for uncontrolled asthma. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 323-6	5.4	5
76	Predictors of depression in chronic obstructive pulmonary disease patients. <i>Expert Review of Respiratory Medicine</i> , 2011 , 5, 333-5	3.8	5
75	Effects of inhaled therapies on health-related quality of life in stable chronic obstructive pulmonary disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010 , 10, 155-62	2.2	5
74	Update on models of pulmonary fibrosis therapy for preclinical drug research. <i>Expert Opinion on Drug Discovery</i> , 2009 , 4, 939-46	6.2	5
73	Targeting the endothelin pathway in the idiopathic pulmonary fibrosis: the role of bosentan. <i>Expert Opinion on Therapeutic Targets</i> , 2008 , 12, 1077-84	6.4	5
72	Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation. <i>Expert Opinion on Investigational Drugs</i> , 2005 , 14, 1443-7	5.9	5
71	Investigational inhaled therapies for non-CF bronchiectasis. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 139-146	5.9	4
70	Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 165-7	3.5	4
69	Evaluation of inhaled tiotropium in asthma, uncontrolled with standard combination therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 967-9	4	4
68	Triple inhaled therapy in stable chronic obstructive pulmonary disease: the earlier, the better? Evaluation of Welte T, Miravittles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. <i>Am J Respir Crit Care Med</i> 2009;180:741-50. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 1039-42	4	4
67	Varenicline for smoking cessation intervention in chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2595-7	4	4
66	Etanercept for refractory asthma therapy. <i>Expert Opinion on Investigational Drugs</i> , 2006 , 15, 1279-81	5.9	4
65	Sildenafil for pulmonary arterial hypertension: when blue turns into white. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 1801-10	4	4

64	Nivolumab for advanced non-small cell lung cancer: an immunologically-mediated tumor checkout. <i>Annals of Translational Medicine</i> , 2016 , 4, 201	3.2	4
63	Benralizumab as a potential treatment of asthma. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 895-909	4	3
62	Palliative care outcome measures in COPD patients: a conceptual review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016 , 16, 267-74	2.2	3
61	Epratuzumab for systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 1045-7	5.4	3
60	Fresh from the designation pipeline: orphan drugs recently designated in the European Union (November 2012 – January 2013). <i>Expert Opinion on Orphan Drugs</i> , 2013 , 1, 499-505	1.1	3
59	Terguride for pulmonary arterial hypertension. <i>Expert Opinion on Therapeutic Targets</i> , 2011 , 15, 1333-5	6.4	3
58	Tiotropium in the treatment of asthma. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 489-91	4	3
57	Inhaled corticosteroids in COPD: systemic effects of a local therapy?. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 3271-3	4	3
56	Somatostatin analogs for idiopathic pulmonary fibrosis therapy. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 1137-40	5.9	3
55	PDE5 inhibitors for cystic fibrosis: can they also enhance chloride transport? Evaluation of: Lubamba B, Lecourt H, Lebacq J, et al. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. <i>Am J Respir Crit Care Med</i> 2008;177(5):506-15. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 965-8	5.9	3
54	Inhaled therapy for stable chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 777-85	4	3
53	Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. <i>N. Engl. J. Med.</i> (2006) 354(25):2655-2666. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 393-5	5.9	3
52	Novel amikacin inhaled formulation for the treatment of lower respiratory tract infections. <i>Drugs of Today</i> , 2013 , 49, 683-92	2.5	3
51	Pulmonologists Adherence to the Chronic Obstructive Pulmonary Disease GOLD Guidelines: A Goal to Improve. <i>Medicina (Lithuania)</i> , 2020 , 56,	3.1	3
50	Determinants of the Hesitancy toward COVID-19 Vaccination in Eastern European Countries and the Relationship with Health and Vaccine Literacy: A Literature Review. <i>Vaccines</i> , 2022 , 10, 672	5.3	3
49	Pharmacotherapy options in pulmonary alveolar proteinosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 1359-1366	4	2
48	Belimumab and antipneumococcal vaccination in patients with systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2018 , 14, 175-177	5.1	2
47	Extra-respiratory symptoms in patients hospitalized for a COPD exacerbation: Prevalence, clinical burden and their impact on functional status. <i>Clinical Respiratory Journal</i> , 2019 , 13, 735-740	1.7	2

46	Efficacy of budesonide in collagenous colitis Evaluation of: Miehlike S, Madisch A, Kupcinskas L, et al. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. <i>Gastroenterology</i> 2014;146(5):1222-1230 e1222. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 2277-9	4	2
45	Bedoradrine for treating asthma and chronic obstructive pulmonary disease. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 1149-56	5.9	2
44	Fresh from the designation pipeline: orphan drugs recently designated in the European Union (September [November 2013]). <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 311-315	1.1	2
43	Tiotropium therapy and mortality risk in COPD patients: the most severe, the most protected? Evaluation of Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. <i>Am J Respir Crit Care Med</i> 2009; 180(10): 948-55. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 1439-41	4	2
42	Targeting platelet-derived growth factor with imatinib in idiopathic pulmonary arterial hypertension. <i>Expert Opinion on Therapeutic Targets</i> , 2009 , 13, 381-3	6.4	2
41	Targeting the Toll-like receptor 7 pathway in asthma: a potential immunomodulatory approach?. <i>Expert Opinion on Therapeutic Targets</i> , 2011 , 15, 667-9	6.4	2
40	Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 423-5	5.9	2
39	Acidinium bromide in experimental asthma. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 871-3	5.9	2
38	Non-prostanoid prostacyclin agonists for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2006 , 15, 327-30	5.9	2
37	Histone deacetylase pathway: an evolving therapeutic target in chronic obstructive pulmonary disease. <i>Expert Opinion on Therapeutic Targets</i> , 2006 , 10, 329-32	6.4	2
36	Formoterol as a rescue medication for asthma. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 2439-41	4	2
35	Evaluating revefenacin as a therapeutic option for chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 997-1004	4	1
34	Asthma and pregnancy: therapeutic challenges. <i>Archives of Gynecology and Obstetrics</i> , 2014 , 290, 621-7	2.5	1
33	Fresh from the designation pipeline: orphan drugs recently designated in the European Union. <i>Expert Opinion on Orphan Drugs</i> , 2013 , 1, 249-253	1.1	1
32	Fresh from the designation pipeline: orphan drugs designated in the European Union (November [December 2014]). <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 719-725	1.1	1
31	Immune therapies for malignant mesothelioma. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 965-73	3.5	1
30	Fresh from the designation pipeline: orphan drugs recently designated in the European Union (June [August 2013]). <i>Expert Opinion on Orphan Drugs</i> , 2013 , 1, 1063-1071	1.1	1
29	Discontinued drugs 2008: pulmonary and allergy. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 1799-805	3.9	1

28	Effects of montelukast-desloratadine combination on early and late asthma responses Davis BE, Illamperuma C, Gauvreau GM, et al. Single-dose desloratadine and montelukast and allergen-induced late airway responses. <i>Eur Respir J</i> 2009;33(6):1302-308. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2577-9	4	1
27	Inhaled phosphodiesterase type 5 inhibitors for cystic fibrosis: a new therapy for systemic disease?. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 713-5	5.9	1
26	Roflumilast as add-on therapy to conventional inhalers in COPD: a cost-effectiveness analysis. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 315-7	2.1	1
25	Fudosteine effects on mucin production. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 105-7	5.9	1
24	Ciclesonide therapy in asthma: a potential effect on small airway inflammation?. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 917-9	4	1
23	Discontinued drugs, 2007: pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1651-61	5.9	1
22	Daily versus intermittent corticosteroids for the treatment of mild persistent asthma. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1235-8	4	1
21	Targeting tumour necrosis factor-alpha in corticosteroid-dependent asthma. <i>Expert Opinion on Therapeutic Targets</i> , 2006, 10, 471-3	6.4	1
20	Frailty, a Dimension of Impaired Functional Status in Advanced COPD: Utility and Clinical Applicability. <i>Medicina (Lithuania)</i> , 2021, 57,	3.1	1
19	Romanian Guidelines for the Diagnosis and Treatment of GERD-induced Respiratory Manifestations.. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2022, 31, 119-142	1.4	1
18	Inhaled interferons beta and SARS-COV2 infection: a preliminary therapeutic perspective. <i>Expert Review of Respiratory Medicine</i> , 2021, 1-5	3.8	0
17	Pharmacological strategies for smoking cessation in patients with chronic obstructive pulmonary disease: a pragmatic review. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 835-847	4	0
16	Treatment of fibrous dysplasia: focus on denosumab.. <i>Expert Opinion on Biological Therapy</i> , 2021, 1-9	5.4	0
15	Efficacy of indacaterol as a single therapy versus salmeterol/fluticasone therapy in patients with milder chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1539-41	4	
14	Fresh from the designation pipeline: orphan drugs recently designated in the European Union (August-October 2014). <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 321-328	1.1	
13	Fresh from the designation pipeline: orphan drugs recently designated in the European Union (December 2013-February 2014). <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 635-641	1.1	
12	Fresh from the designation pipeline: orphan drugs recently designated in the EU (June-July 2014). <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 1309-1313	1.1	
11	Outpatient palliative care effectiveness: both patients and caregivers can gain. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 575-7	2.2	

10	Fresh from the designation pipeline: orphan drugs recently designated in the European Union (March [April 2013). <i>Expert Opinion on Orphan Drugs</i> , 2013 , 1, 765-768	1.1
9	Outcome measures for palliative oxygen therapy: relevance and practical utility. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014 , 14, 417-23	2.2
8	Fresh from the designation pipeline: orphan drugs recently designated in the EU (March [April 2014). <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 957-960	1.1
7	Discontinued drugs for pulmonary, allergy, gastrointestinal, arthritis (2012). <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 1453-64	5.9
6	Health status and chronic obstructive pulmonary disease severity. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011 , 11, 399-401	2.2
5	Discontinued drugs 2010: rheumatology, allergy and dermatology, pulmonary. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 1175-87	5.9
4	Itraconazole for severe asthma with fungal sensitivity. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 1231-3	4
3	Bosentan for the treatment of idiopathic pulmonary fibrosis. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 611-4	5.9
2	Long-term bronchodilator inhaled therapy in COPD: the role of tiotropium bromidum. <i>Reviews on Recent Clinical Trials</i> , 2009 , 4, 89-98	1.2
1	Humanistic Outcomes and Quality of Life 2012 , 211-220	